Avenge Bio

Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.

Zeke Johnston - Senior Director, External Manufacturing & Supply Chain at Avenge Bio

Douglas Carlson on LinkedIn: Avenge Bio Announces Dosing of First Patient in Phase 1/2 Clinical Trial…

Stanley Tam email address & phone number Avenge Bio Corporate Controller contact information - RocketReach

avengebio (@AvengeBio) / X

Avenge Bio announces peer-reviewed publication on preclinical proof of concept for LOCOcyte platform technology

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

avengebio (@AvengeBio) / X

Avenge Bio Archives - THELANSIS

Zeke Johnston - Senior Director, External Manufacturing and Supply Chain - Avenge Bio

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

Rice lab's 'drug factory' implants cleared for human trials, Rice News, News and Media Relations

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors